Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
GENE - Genetic Technologies Ltd.
$4.30
-0.07(-1.60%)9:00:00 PM 1/20/2021
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    12/2/2020GENE
    Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

    MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”). Key Highlights * Expands GTG’s product offering and establishes the mental health vertical through distribution partnershi...

    12/1/2020GENE
    Have Insiders Been Buying Genetic Technologies Limited (ASX:GTG) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

    11/23/2020GENE
    Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report

    MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the exclusive interview, Dr. Muchnicki discusses the Company’s innovative d...

    11/17/2020GENE
    Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19

    MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company’s recent developments during an investor webinar on Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation. To participate in the webinar, please register at: https://www.redchip.com/corporate/w...

    10/1/2020GENE
    Genetic Technologies Provides Update on COVID-19 Risk Test

    Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on the development of the Company’s COVID-19 Risk Test. Genetic Technologies has outlined additional findings in relation to its COVID-19 Risk Test.

    09/15/2020GENE
    Genetic Technologies Provides Update on COVID-19 Disease Severity Test Development

    MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable an assessment of risk of an individual developing a serious disease should they contract the virus. The test is intended to predict ‘disease severity’ using a combination of genetic and clinical information. The Company is pleased...

    09/11/2020GENE
    Genetic Technologies Announces US Sales Have Commenced via Online Health Platform

    MELBOURNE, Australia, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced in the United States via an online health platform, elicity by InTeleLabs, an independent telehealth and personalised medicine company. This portal is secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant.The secure...